Literature DB >> 12693607

Cytokines, stress and depressive illness: brain-immune interactions.

Hymie Anisman1, Zul Merali.   

Abstract

Cytokines, signaling molecules of the immune system, have been implicated as a contributing factor for mood disorders such as depression. Several lines of evidence supporting this contention are briefly reviewed and caveats are introduced. Essentially, a relationship between cytokines and depression is based on the findings that: 1) proinflammatory cytokines (interleukin-1, interleukin-6, tumor necrosis factor-alpha) and bacterial endotoxins elicit sickness behaviors (e.g., fatigue, soporific effects) and symptoms of anxiety/depression that may be attenuated by chronic antidepressant treatment, 2) cytokines induce neuroendocrine and central neurotransmitter changes reminiscent of those implicated in depression, and these effects are exacerbated by stressors, 3) severe depressive illness is accompanied by signs of immune activation and by elevations of cytokine production or levels, and 4) immunotherapy, using interleukin-2 or interferon-alpha, promotes depressive symptoms that are attenuated by antidepressant treatment. It is argued that cytokine synthesis and release, elicited upon activation of the inflammatory response system, provoke neuroendocrine and brain neurotransmitter changes that are interpreted by the brain as being stressors, and contribute to the development of depression. Furthermore, such effects are subject to a sensitization effect so that a history of stressful experiences or cytokine activation augment the response to later challenges and hence the evolution of depression

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12693607     DOI: 10.1080/07853890310004075

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  81 in total

Review 1.  Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.

Authors:  George R Breese; Rajita Sinha; Markus Heilig
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

Review 2.  Pharmacogenomics of suicidal events.

Authors:  David Brent; Nadine Melhem; Gustavo Turecki
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

Review 3.  Humoral sleep regulation; interleukin-1 and tumor necrosis factor.

Authors:  Kathryn A Jewett; James M Krueger
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

4.  Anti-streptococcus IgM antibodies induce repetitive stereotyped movements: cell activation and co-localization with Fcα/μ receptors in the striatum and motor cortex.

Authors:  Danhui Zhang; Ankur Patel; Youhua Zhu; Allan Siegel; Steven S Zalcman
Journal:  Brain Behav Immun       Date:  2012-01-21       Impact factor: 7.217

Review 5.  Biochemical regulation of sleep and sleep biomarkers.

Authors:  James M Clinton; Christopher J Davis; Mark R Zielinski; Kathryn A Jewett; James M Krueger
Journal:  J Clin Sleep Med       Date:  2011-10-15       Impact factor: 4.062

Review 6.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 7.  The role of cytokines in sleep regulation.

Authors:  James M Krueger
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 8.  Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.

Authors:  Eleonore Beurel
Journal:  Neuroimmunomodulation       Date:  2014-02-14       Impact factor: 2.492

9.  Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression.

Authors:  Jean-Eric Ghia; Patricia Blennerhassett; Stephen M Collins
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.

Authors:  Firoza Mamdani; Marcelo T Berlim; Marie-Martine Beaulieu; Gustavo Turecki
Journal:  World J Biol Psychiatry       Date:  2013-03-26       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.